“Groundbreaking Eli Lilly’s Tirzepatide: 15.7% Weight Loss Success for Overweight Diabetics Revealed!”
Eli Lilly & Co. recently reported that its tirzepatide achieved remarkable weight loss results in adult participants with obesity or overweight and type 2 diabetes during a late-stage trial. The phase 3 trial, Surmount-2, involved 938 adults and aimed to evaluate the drug as a treatment for chronic weight management. The trial showed up to […]